Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts

LaTronya T McCollum1, Patricia E Gallagher, E Ann Tallant

  • 1The Hypertension and Vascular Research Center, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1032, USA.

Peptides
|February 14, 2012
PubMed

Insights

Angiotensin-(1-7) [Ang-(1-7)] reduces cardiac fibroblast proliferation and collagen synthesis by up-regulating DUSP1 and decreasing mitogenic prostaglandins. This peptide hormone may prevent cardiac fibrosis.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Fibrosis Research

Background:

  • Angiotensin-(1-7) [Ang-(1-7)] is known to reduce cardiac fibrosis.
  • The specific molecular mechanisms by which Ang-(1-7) acts on cardiac fibroblasts were previously unidentified.

Purpose of the Study:

  • To investigate the signaling pathways activated by Ang-(1-7) in cardiac fibroblasts.
  • To elucidate the role of Ang-(1-7) in regulating fibroblast proliferation and collagen synthesis.

Main Methods:

  • Primary neonatal rat cardiac fibroblasts were isolated.
  • Cells were treated with Ang-(1-7) and stimulated with serum or endothelin-1 (ET-1).
  • Incorporation of (3)H-thymidine, -leucine, and -proline was measured; Western blotting and real-time PCR were used to assess protein and mRNA levels of key signaling molecules (e.g., phospho-ERK1/2, DUSP1, COX-2, PGES).

Main Results:

  • Ang-(1-7) significantly reduced DNA, protein, and collagen synthesis in a receptor-specific manner.
  • Ang-(1-7) decreased the ET-1-induced phosphorylation of ERK1/2 by increasing DUSP1 expression.
  • Ang-(1-7) inhibited the ET-1-stimulated increase in cyclooxygenase 2 (COX-2) and prostaglandin synthase (PGES) mRNA levels.

Conclusions:

  • Ang-(1-7) maintains cardiac homeostasis by inhibiting cardiac fibroblast proliferation and collagen production.
  • The mechanism involves up-regulation of DUSP1 to reduce MAP kinase activity and attenuation of mitogenic prostaglandin synthesis.
  • Therapeutic strategies targeting Ang-(1-7) could be beneficial in preventing cardiac fibrosis.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...